Novo’s Fiasp insulin cleared by FDA for use with Insulet’s Omnipod

Insulet (NASDAQ:PODD) announces that the FDA has cleared the use of Novo Nordisk’s (NYSE:NVO) ultra-fast-acting insulin aspart Fiasp with its Omnipod Insulin Management System and Omnipod DASH Insulin Management System for adults.

Fiasp is the only fast-acting insulin that does not require pre-meal dosing.

Omnipod is been approved for use with Fiasp since October 2018 in Europe.

https://seekingalpha.com/news/3509634-novos-fiasp-insulin-cleared-fda-use-insulets-omnipod